Background It remains essential for non-alcoholic fatty liver (NAFLD) patients, to develop a sensitive and specific diagnostic model. Data regarding the use of micro (mi)RNA-34 for NAFLD diagnosis are few. Routine clinical assessment, laboratory tests were done for Egyptian individuals (n = 314) were included (100 healthy individuals and 214 NAFLD patients). Quantification of miRNA-34 was done using real-time PCR. Extremely significant variables were entered into stepwise logistic regression. The diagnostic power of variables was estimated by the area under the ROC (AUC). Results MiRNA-34 levels were higher in NAFLD patients than healthy individuals with a significant difference (P< 0.0001). The multivariate analysis was used to evaluate the NAFLD-associated variables (CRP, cholesterol, body mass index (BMI), ALT had p< 0.0001 while mRNA-34 had (p=0.0004). The AUCs (CI) of candidate NAFLD markers were in the order of miRNA-34 0.72 (0.66–0.77) < ALT 0.73 (0.67–0.79) < BMI 0.81 (0.76–0.86) < cholesterol < 0.85 (0.79–0.90) < CRP 0.88 (0.84–0.92). We developed a novel index for discriminating patients with NAFLD named NAFLD Mark. AUC was jumped to 0.98 (0.93–0.99) when five markers were combined. The AUC of NAFLD mark for NAFLD detection was higher than the AUCs of seven common NAFLD indexes (0.44–0.86). Conclusions The NAFLD mark is a non-invasive and highly sensitive and specific model for NAFLD diagnosis.
(1) Background: Type 2 diabetes mellitus (T2DM) is one of the rapidly growing healthcare problems, and several vitamin D receptor (VDR) polymorphisms seem to modulate the risk of T2DM. Our research was designed to investigate the allelic discrimination of VDR polymorphisms and T2DM occurrence risk. (2) Methods: This case-control research included 156 patients with T2DM and 145 healthy control subjects. Most of the study population were males 56.6% vs. 62.8% in the case and control groups, respectively. Genotyping for VDR single nucleotide polymorphisms (SNPs), rs228570 (Fok1), rs7975232 (Apa1), and rs1544410 (Bsm1) was compared between both groups. (3) Results: There was a negative link between vitamin D levels and insulin sensitivity. A significant difference was noted in the allelic discrimination of VDR polymorphism rs228570 and rs1544410 between the study groups (p < 0.001). No difference was observed in the allelic discrimination of VDR polymorphism rs7975232 between the groups (p = 0.063). Moreover, T2DM patients had significantly higher levels of fasting blood sugar (FBS), glycated hemoglobin HbA1c, 2-h post-prandial blood sugar (PP), serum glutamic oxaloacetic transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT), total cholesterol, and triglycerides (p < 0.001), while High-Density Lipoprotein (HDL) Cholesterol (HDL-C) was significantly decreased (p = 0.006). (4) Conclusions: VDR polymorphisms had a positive association with T2DM risk among the Egyptian population. Further large-scale research using deep sequencing of samples is strongly urged to investigate different vitamin D gene variants and interactions, as well as the influence of vitamin D on T2DM.
Background: Coronavirus Disease 2019 (COVID-19) is a paramount public health issue. The true statistics about COVID-19 in Egypt are veiled. Aim: To determine the incidence rate of moderate and severe SARS-CoV-2 infection among the patients seeking admission to Zagazig University Hospitals (ZUH), Egypt based on the chest Computed Tomography (CT) COVID-19 Reporting and Data System (CO-RADS) radiological criteria. Methods: All patients aged ≥ 18 years old seeking admission to ZUH between January 1 st and March 31 st , 2021, were eligible for enrollment in the study if they performed non-enhanced chest CT. Assessment of clinical, laboratory, and chest CT CO-RADS radiological criteria for each patient was carried out. The patients were defined to have moderate or severe COVID-19 if they met CO-RADS 4 or 5 radiological criteria, respectively, in association with the clinical and/or laboratory criteria. Results: A total of 5549 subjects were enrolled in the study. The total number of moderate and severe COVID-19 cases diagnosed at ZUH during January 2021 was 434/1827 with a monthly incidence rate of 23.75; 95% CI (21.9-25.8) per 100.000 of the population. The total number of moderate and severe COVID-19 cases during February 2021 was 215/1622 with a monthly incidence rate of 13.25;. During March, the total number of moderate and severe COVID-19 cases was 416/2100 with a monthly incidence rate of 19.8; 95% CI (18.2-21.6). Conclusion: The incidence rate of moderate and severe COVID-19 infection at ZUH is in parallel with the national COVID-19 incidence reports.
Background: In many health systems, primary care is the main source of health care services. Liver cirrhosis is a silent disease that causes no signs or symptoms until decompensation occurs. Therefore, a simple and readily accessible tool for predicting advanced liver fibrosis and cirrhosis is needed to aid general practitioners in primary care settings. Aim: To explore the predictive performance of Albumin Bilirubin (ALBI) score as a non-invasive serum biomarker for advanced liver fibrosis and cirrhosis. Methods:This case-control study was conducted at Zagazig University Hospitals, Egypt, and comprised 400 participants divided into two equal groups. Group (I): 200 chronic HCV patients with advanced liver fibrosis and cirrhosis [F3-F4] and Group (II): 200 healthy controls. ALBI score was calculated for all study participants. Results: The AUROC for the ALBI score was 0.832 (95% CI: 0.787-0.872) (p-value <0.001), sensitivity= 74.8%, specificity= 80.2%, PPV= 86.8%, NPV =64.6%, and positive likelihood ratio=3.77. The cut-off value to differentiate chronic HCV patients with advanced liver fibrosis and cirrhosis from healthy controls was -2.781. Sub-group analysis of chronic HCV cases showed a statistically significant difference in the mean ALBI score between (F3) and (F4) cases (p-value<0.0001) with an AUROC of 0.654 (p-value=0.028). Conclusion: ALBI score is reliable for predicting advanced liver fibrosis and cirrhosis and could be valuable in primary care.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.